Previous article Next article

The EU Court of Justice clarifies when patent settlement agreements restricting a generic pharmaceutical company’s ability to enter the market, infringe EU antitrust rules (Generics UK / GlaxoSmithKline)

Article summary: Settlement Agreements Can Be Anti-Competitive Only If The Involved Companies Are (At Least) Potential Competitors. A Careful Examination Must Determine Whether A Generic Manufacturer Would Have Entered Into The Market Without A "Pay Per Delay" Agreement. The Classification Of This Kind Of Patent Agreement As A Restriction Of Competition "By Object" Is Not Self-Evident. Whether There Is A Restriction "By Effect" It Must Be Determined Based On A Prospective Analysis Of The Market In The Absence Of The Concerted Practice. The Assessment Of A Dominant Position Of A Patent Holder Requires Balancing The Anti-Competitive Effects Of The Allegedly Abusive Conduct And Its Efficiencies. Introduction On 30 January 2020, the Court of Justice of the European Union (the ‘CJEU’)

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Anne Federle, Pauline Van Sande, The EU Court of Justice clarifies when patent settlement agreements restricting a generic pharmaceutical company’s ability to enter the market, infringe EU antitrust rules (Generics UK / GlaxoSmithKline), 30 January 2020, e-Competitions Preview, Art. N° 95846

Visites 9

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues